breast cancer
News/ News/ News/ Oncology/ Sales and Marketing
AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy
Phil Taylor
adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology
0 Comment
FDA verdict on Enhertu in HER2-low breast cancer due before year-end
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, fda, her2, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa
0 Comment
Market Access/ News/ News/ News/ Oncology
Byondis cues up US, EU decisions on breast cancer ADC in 2023
Phil Taylor
AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche
0 Comment
Market Access/ News/ News/ News/ Oncology
NICE backs two new breast cancer drugs for NHS use
Phil Taylor
breast cancer, Gilead Sciences, HEOR, NHS, NICE, Novartis, Oncology, Piqray, Trodelvy
0 Comment
Market Access/ News/ News/ News/ News/ Oncology/ Patients
Lilly’s Verzenios gets NICE blessing for early-stage breast cancer
Phil Taylor
breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio
0 Comment
Lilly partners with Sidekick in digital health alliance
Phil Taylor
breast cancer, digital, digital health, digital therapeutics, Eli Lilly, Oncology, partnering, Sidekick Health
0 Comment
Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
Redefining the approach to cancer care – a mission to improve patient outcomes
mike.hammerton@pharmaphorum.com
breast cancer, cancer care, company profile, Exact Sciences, her2
0 Comment